Biotech | Traders & Quants

Biotech

Articles

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

March 13, 2025

·

Benzinga

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

March 11, 2025

·

Benzinga

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

March 7, 2025

·

Benzinga

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

March 4, 2025

·

Benzinga

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future

March 4, 2025

·

Benzinga

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

January 9, 2025

·

Benzinga

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)

January 8, 2025

·

Benzinga

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

January 3, 2025

·

Benzinga

Enjoy premium content in your inbox.

You're in! Check your email to learn more.

Oops! Something went wrong while submitting the form.